Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Contact

2020 shows promise in the fight for a mesothelioma cure

by Brayton Purcell LLP | Jan 4, 2021 | Mesothelioma

pills and thermometer on a table

Media coverage in 2020 surrounded a particular virus and the progress made in defeating it. Similarly, new treatments, drug regimens, and cutting-edge and highly successful trials gave a glimmer of hope to those suffering from mesothelioma, not to mention their family members.

Some of the more prominent stories included:

The FDA approves Keytruda

Pembrolizumab, an immunotherapy drug, was approved in June for certain metastatic tumors. A select number of those patients suffered from pleural mesothelioma. Earlier trials of Keytruda (the formal brand name) revealed promising results in its effectiveness with a handful of patients. While doctors do not refer to it as a cure, success in the trial does represent a step forward and provides patients a chance, however small, in the continuing fight against this deadly form of cancer.

Italy’s asbestos ban starts to show results

Unlike the United States, Italy took steps to formally ban asbestos nearly thirty years ago. Medical experts are seeing a peak in the health crisis that spurred the stoppage. However, evidence of a prohibition’s effectiveness remains scant. The medical industry must continue pursuing a cure, as formal diagnoses of mesothelioma still take up to 50 years. Proactive measures are paramount due to the disease’s sinister slowness in showing itself.

Approval of immunotherapy

It may have taken 16 years, but in October, the U.S. Food and Drug Administration approved a new drug treatment regimen in the fight against malignant pleural mesothelioma cancer. Findings from an international phase III clinical trial saw increased survival rates from nine months with chemotherapy to slightly over 18 months with immunotherapy combinations.

A cure remains elusive. The battle continues. Hopefully, 2021 shows promise and provides more hope.

Recent Posts

  • EPA Risk Evaluation for Chrysotile Asbestos
  • Caring for Someone with Mesothelioma: What to Know
  • 2020 shows promise in the fight for a mesothelioma cure
  • Asbestos in Makeup Products Is a Problem That Is Not Going Away
  • How Did I Get Mesothelioma?

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us